Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.

Autor:	Giri VN; Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA.; Department of Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA.; Department of Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA., Knudsen KE; Department of Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA., Kelly WK; Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA., Cheng HH; Department of Medicine, University of Washington, and Fred Hutchinson Cancer Research Center, Division of Clinical Research, Seattle, WA., Cooney KA; Duke University School of Medicine and Duke Cancer Institute, Durham, NC., Cookson MS; University of Oklahoma College of Medicine, Norman, OK., Dahut W; Genitourinary Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD., Weissman S; National Society of Genetic Counselors, Chicago, IL., Soule HR; Prostate Cancer Foundation, Santa Monica, CA., Petrylak DP; Yale Cancer Center, New Haven, CT., Dicker AP; Department of Radiation Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA., AlDubayan SH; Dana-Farber Cancer Institute, Boston, MA., Toland AE; Department of Cancer Biology and Genetics, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio., Pritchard CC; Department of Laboratory Medicine, University of Washington, Seattle, WA., Pettaway CA; The University of Texas MD Anderson Cancer Center, Houston, TX., Daly MB; Fox Chase Cancer Center, Philadelphia, PA., Mohler JL; Roswell Park Comprehensive Cancer Center, Buffalo, NY., Parsons JK; Moores UC San Diego Comprehensive Cancer Center, San Diego, CA., Carroll PR; Department of Urology, University of California, San Francisco, San Francisco, CA., Pilarski R; James Comprehensive Cancer Center and Department of Internal Medicine, The Ohio State University, Columbus, OH., Blanco A; University of California, San Francisco, Cancer Genetics and Prevention Program, San Francisco, CA., Woodson A; The University of Texas MD Anderson Cancer Center, Houston, TX., Rahm A; Center for Health Research, Genomic Medicine Institute, Geisinger, Danville, PA., Taplin ME; Dana-Farber Cancer Institute, Boston, MA., Polascik TJ; Duke University Medical Center, Durham, NC., Helfand BT; North Shore University Health System, Evanston, IL., Hyatt C; Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA., Morgans AK; Northwestern University, Chicago, IL., Feng F; Departments of Radiation Oncology, Urology, and Medicine, University of California, San Francisco, San Francisco, CA., Mullane M; Advocate Aurora Health, Milwaukee, WI., Powers J; University of Pennsylvania, Basser Center for BRCA, Philadelphia, PA., Concepcion R; Integra Connect, West Palm Beach, FL., Lin DW; University of Washington, Seattle, WA., Wender R; American Cancer Society, Atlanta, GA., Mark JR; Department of Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA., Costello A; Urology at Royal Melbourne Hospital, North Melbourne, VIC, Australia., Burnett AL; Johns Hopkins Medical Institutions, Baltimore, MD., Sartor O; Tulane University, New Orleans, LA., Isaacs WB; Brady Urological Institute, Johns Hopkins Medicine, Baltimore, MD., Xu J; North Shore University Health System, Evanston, IL., Weitzel J; City of Hope Comprehensive Cancer Center, Duarte, CA., Andriole GL; Washington University School of Medicine, St Louis, MO., Beltran H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Briganti A; Unit of Urology, Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy., Byrne L; The Ohio State University, Columbus, OH., Calvaresi A; Department of Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA., Chandrasekar T; Department of Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA., Chen DYT; Fox Chase Cancer Center, Philadelphia, PA., Den RB; Department of Radiation Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA., Dobi A; Henry Jackson Foundation for the Advancement of Military Medicine, Center for Prostate Disease Research, Department of Surgery, Uniformed Services University and the Walter Reed National Military Medical Center, Bethesda, MD., Crawford ED; University of California, San Diego, La Jolla, CA., Eastham J; Memorial Sloan Kettering Cancer Center, New York, NY., Eggener S; University of Chicago, Chicago, IL., Freedman ML; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Garnick M; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA., Gomella PT; National Cancer Institute, National Institutes of Health, Bethesda, MD., Handley N; Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA., Hurwitz MD; Department of Radiation Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA., Izes J; Department of Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA., Karnes RJ; Mayo Clinic, Rochester, MN., Lallas C; Department of Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA., Languino L; Department of Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA., Loeb S; Department of Urology and Population Health, New York University and Manhattan Veterans Affairs, New York, NY., Lopez AM; Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA., Loughlin KR; Harvard Medical School, Boston, MA., Lu-Yao G; Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA., Malkowicz SB; University of Pennsylvania, Philadelphia, PA., Mann M; Department of Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA., Mille P; Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA., Miner MM; Brown University, Providence, RI., Morgan T; University of Michigan, Ann Arbor, MI., Moreno J; Midlantic Urology, Phoenixville, PA., Mucci L; Department of Epidemiology, Harvard TH Chan School of Public Health, Boston MA., Myers RE; Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA., Nielsen SM; University of Chicago, Chicago, IL., O'Neil B; University of Utah, Huntsman Cancer Institute, Salt Lake City, UT., Pinover W; Abington-Jefferson Hospital, Abington, PA., Pinto P; National Cancer Institute, National Institutes of Health, Bethesda, MD., Poage W; Prostate Conditions Education Council, Elizabeth, CO., Raj GV; University of Texas Southwestern Medical Center at Dallas, Dallas, TX., Rebbeck TR; Department of Epidemiology, Harvard TH Chan School of Public Health, Boston MA., Ryan C; University of Minnesota and Masonic Cancer Center, Madison, WI., Sandler H; Cedars-Sinai Medical Center, Los Angeles, CA., Schiewer M; Department of Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA., Scott EMD; Prostate Cancer International, Virginia Beach, VA., Szymaniak B; Northwestern Medical Group, Urology Department, Chicago, IL., Tester W; Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA., Trabulsi EJ; Department of Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA., Vapiwala N; University of Pennsylvania, Philadelphia, PA., Yu EY; University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA., Zeigler-Johnson C; Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA., Gomella LG; Department of Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA.
Jazyk:	angličtina
Zdroj:	Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2020 Aug 20; Vol. 38 (24), pp. 2798-2811. Date of Electronic Publication: 2020 Jun 09.
DOI:	10.1200/JCO.20.00046
Abstrakt:	Purpose: Germline testing (GT) is a central feature of prostate cancer (PCA) treatment, management, and hereditary cancer assessment. Critical needs include optimized multigene testing strategies that incorporate evolving genetic data, consistency in GT indications and management, and alternate genetic evaluation models that address the rising demand for genetic services. Methods: A multidisciplinary consensus conference that included experts, stakeholders, and national organization leaders was convened in response to current practice challenges and to develop a genetic implementation framework. Evidence review informed questions using the modified Delphi model. The final framework included criteria with strong (> 75%) agreement (Recommend) or moderate (50% to 74%) agreement (Consider). Results: Large germline panels and somatic testing were recommended for metastatic PCA. Reflex testing-initial testing of priority genes followed by expanded testing-was suggested for multiple scenarios. Metastatic disease or family history suggestive of hereditary PCA was recommended for GT. Additional family history and pathologic criteria garnered moderate consensus. Priority genes to test for metastatic disease treatment included BRCA2, BRCA1, and mismatch repair genes, with broader testing, such as ATM , for clinical trial eligibility. BRCA2 was recommended for active surveillance discussions. Screening starting at age 40 years or 10 years before the youngest PCA diagnosis in a family was recommended for BRCA2 carriers, with consideration in HOXB13, BRCA1, ATM , and mismatch repair carriers. Collaborative (point-of-care) evaluation models between health care and genetic providers was endorsed to address the genetic counseling shortage. The genetic evaluation framework included optimal pretest informed consent, post-test discussion, cascade testing, and technology-based approaches. Conclusion: This multidisciplinary, consensus-driven PCA genetic implementation framework provides novel guidance to clinicians and patients tailored to the precision era. Multiple research, education, and policy needs remain of importance.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu